MENU
SEER
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SEER stock forecast, quote, news & analysis

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome... Show more

SEER
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SEER with price predictions
Sep 28, 2026

SEER in upward trend: price rose above 50-day moving average on September 28, 2026

SEER moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SEER's RSI Indicator exited the oversold zone, 22 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Momentum Indicator moved above the 0 level on September 28, 2026. You may want to consider a long position or call options on SEER as a result. In 61 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for SEER just turned positive on September 28, 2026. Looking at past instances where SEER's MACD turned positive, the stock continued to rise in 35 of 50 cases over the following month. The odds of a continued upward trend are 70%.

Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where SEER advanced for three days, in 163 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for SEER crossed bearishly below the 50-day moving average on August 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SEER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

SEER broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SEER entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.469) is normal, around the industry mean (26.424). P/E Ratio (0.000) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.800) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. SEER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SEER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 133.37B. VRTX holds the highest valuation in this group at 133.37B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 4%. KOD experienced the highest price growth at 177%, while LONA experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 42% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 62
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
SEER
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3800 Bridge Parkway
Phone
+1 650 453-0000
Employees
124
Web
https://www.seer.bio
SEER in upward trend: price rose above 50-day moving average on September 28, 2026